C. Kortsik - Concepedia

Author

C. Kortsik

Also Known As

C KORTSIK, C Kortsik, C St Kortsik, C. Kortsik, C. S. Kortsik, C. St. F. Kortsik, C.St.F. Kortsik, Cornelius Kortsik, Kortsik, Cornelius

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Johannes Gutenberg University Mainz University Medical Center Freiburg University Medical Center of the Johannes Gutenberg University Mainz Heidelberg University LungenClinic Grosshansdorf

About

C. Kortsik is an author at Johannes Gutenberg University Mainz specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.1K
2	Health Sciences	2	2	23
3	Nursing	2	2	96
4	Public Health	1	1	12
5	Allergy	1	1	217

C. Kortsik

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
T Cells and Cytokines in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Atopic Asthma J. Christian Virchow, Christoph Walker, D. Häfner, American Journal of Respiratory and Critical Care Medicine AsthmaLung InflammationAllergy MedicineImmunologyImmune Regulation	1995	217
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma C. Manegold, James T. Symanowski, U. Gatzemeier, Annals of Oncology Malignant Pleural MesotheliomaMedicinePhase Iii TrialPathologyPleural Disease	2005	157
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial Giorgio V. Scagliotti, C. Kortsik, G. Dark, Clinical Cancer Research	2005	137
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial Martin Sebastian, Martin Reck, Cornelius F. Waller, Journal of Thoracic Oncology Bi 2536Novel Plk-1 InhibitorMedicinePathologyImmune Checkpoint Inhibitor	2010	109
Highly Focused T Cell Responses in Latent Human Pulmonary <i>Mycobacterium tuberculosis</i> Infection Glenn Tully, C. Kortsik, Hanni Höhn, The Journal of Immunology Adaptive Immune SystemTuberculosis PreventionImmunologyImmunodominanceAntigen Processing	2005	102
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study Kenneth J. O’Byrne, Igor Bondarenko, Carlos Barrios, Journal of Clinical Oncology Malignant DiseaseMedicineKras MutationFlex StudyPathology	2009	92
Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group Eckart Laack, N. Dickgreber, Thomas Müller, Journal of Clinical Oncology	2004	90
Quality of Life in NSCLC Survivors — A Multicenter Cross-Sectional Study Marlene Hechtner, Martin Eichler, Beatrice Wehler, Journal of Thoracic Oncology NursingFamily MedicineQuality Of LifeLife AssessmentOutcomes Research	2018	84
Severe Barium Sulfate Aspirationinto the Lung: Clinical Presentation, Prognosis and Therapy Ingo Tamm, C. Kortsik Respiration Acute Lung InjuryTracheobronchitisRadiographic Contrast ProceduresInterventional PulmonologyClinical Presentation	1999	56
Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis Frank Weichold, Stefanie Mueller, C. Kortsik, Genes and Immunity ImmunogeneticsPulmonary TuberculosisMhc ClassAdaptive Immune SystemImmunology	2007	46

Page 1